Teva Pharmaceutical Industries Ltd.

Leading Access to Medicine Practices

No leading practice identified for this company. 

Changes Compared to Index 2008

• Teva made a record-sized multi-drug donation valued at GBP 12.1 million (or 2 million treatments) to the Index Countries through International Health Partners (IHP), during the survey period.
• Currently Teva has no ATM policies, objectives or governance representation. There are no changes in the company's overall approach compared to Index 2008.
• The company's only emerging markets strategy in Eastern Europe and Latin America is focused on "Authorized Generics", which is not conducive to generic competition and increased affordability.

Suggested Areas for Improvement

• Unlike most of its peers, Teva does not have a strategic focus on ATM and it lacks senior governance representation and reporting around ATM issues.
• While it is the largest generics company in the sector, the company does not harness its significant market influence to the benefit of ATM in areas such as competition practices, lobbying and advocacy.
• The company has one of the lowest levels of disclosure among the generics companies covered by the Index 2010 .